Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

This study tests niraparib — a targeted drug called a PARP inhibitor — as maintenance therapy in women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors have a DNA repair deficiency (called HRD-positive). The drug is given after completing front-line chemotherapy plus bevacizumab to try to keep the cancer from coming back. **You may be eligible if...** - You are female and 18 or older - You have high-grade ovarian, fallopian tube, or primary peritoneal carcinoma confirmed by biopsy - Your cancer is Stage III or IV - You had surgery to remove as much cancer as possible (primary or interval debulking surgery) - You have completed chemotherapy with bevacizumab - Your tumor is HRD-positive (has a specific DNA repair gene problem, often a BRCA mutation) **You may NOT be eligible if...** - Your tumor is HRD-negative - You have not completed the required chemotherapy regimen - You did not have debulking surgery - You do not meet organ function requirements Talk to your doctor to see if this trial is right for you.